

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>GADICKE ANSBERT</u> <hr/> (Last) (First) (Middle) <u>C/O MPM CAPITAL</u> <u>450 KENDALL STREET</u> <hr/> (Street) <u>CAMBRIDGE MA 02142</u> <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Harpoon Therapeutics, Inc. [ HARP ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>05/21/2021</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/21/2021		s <sup>(1)</sup>		10,907 <sup>(2)</sup>	D	\$20.21 <sup>(3)</sup>	6,407,748	I	See Footnote <sup>(4)</sup>
Common Stock	05/24/2021		s <sup>(1)</sup>		5,000 <sup>(5)</sup>	D	\$20.12 <sup>(6)</sup>	6,402,748	I	See Footnote <sup>(7)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
GADICKE ANSBERT  


---

 (Last) (First) (Middle)  
C/O MPM CAPITAL  
450 KENDALL STREET  


---

 (Street)  
CAMBRIDGE MA 02142  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Oncology Impact Fund (Cayman) Management L.P.  


---

 (Last) (First) (Middle)  
C/O MPM CAPITAL  
450 KENDALL STREET  


---

 (Street)  
CAMBRIDGE MA 02142  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
MPM Oncology Impact Management LP

(Last) (First) (Middle)  
C/O MPM CAPITAL  
450 KENDALL STREET

(Street)  
CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
[MPM Oncology Impact Management GP LLC](#)

(Last) (First) (Middle)  
C/O MPM CAPITAL  
450 KENDALL STREET

(Street)  
CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
[UBS Oncology Impact Fund L.P.](#)

(Last) (First) (Middle)  
C/O MPM CAPITAL  
450 KENDALL STREET

(Street)  
CAMBRIDGE MA 02142

(City) (State) (Zip)

**Explanation of Responses:**

1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.
2. The shares were sold as follows: 9,587 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,320 by MPM Asset Management LLC ("AM LLC").
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.95 to \$20.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 235,085 by AM LLC and 3,266,720 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
5. The shares were sold as follows: 4,395 by UBS Oncology and 605 by AM LLC.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.95 to \$20.355 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 234,480 by AM LLC and 3,262,325 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

**Remarks:**

[/s/ Ansbert Gadicke](#) [05/24/2021](#)  
[/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund \(Cayman\) Management L.P.](#) [05/24/2021](#)  
[/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP](#) [05/24/2021](#)  
[/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC](#) [05/24/2021](#)  
[/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact](#) [05/24/2021](#)

[Management LP, the general partner of Oncology Impact Fund \(Cayman\) Management L.P., the GP of UBS Oncology Impact Fund L.P.](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**